It is testing compounds that block an enzyme, called Lp-PLA2, that attaches to cholesterol particles and chops off globs of fat that attract immune cells into the arteries.
Research into these biologic antibody-based approaches is at an earlier stage than the testing of antagonist drugs, but antibodies eventually might be able to block CGRP action regularly so that migraines don't ever begin.